|
1.Deryugina, E. I.Quigley, J. P., Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev, 2006. 25(1): p. 9-34.
2.Parkin, D. M.Bray, F.Ferlay, J.Pisani, P., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 74-108.
3.Harbeck, N., Never too late: reducing late breast cancer relapse risk. Curr Med Res Opin, 2008. 24(12): p. 3295-305.
4.Lin, S. C.Lin, C. C.Lin, Y. H.Shyuu, S. J., Hepatoprotective effects of Taiwan folk medicine: wedelia chinensis on three hepatotoxin-induced hepatotoxicity. Am J Chin Med, 1994. 22(2): p. 155-68.
5.Lin, F. M.Chen, L. R.Lin, E. H.Ke, F. C.Chen, H. Y.Tsai, M. J.Hsiao, P. W., Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis, 2007. 28(12): p. 2521-9.
6.Tsai, C. H.Lin, F. M.Yang, Y. C.Lee, M. T.Cha, T. L.Wu, G. J.Hsieh, S. C.Hsiao, P. W., Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res, 2009. 15(17): p. 5435-44.
7.Ghosh, S.Gifford, A. M.Riviere, L. R.Tempst, P.Nolan, G. P.Baltimore, D., Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell, 1990. 62(5): p. 1019-29.
8.Vane, J. R.Bakhle, Y. S.Botting, R. M., Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 1998. 38: p. 97-120.
9.Fosslien, E., Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci, 2000. 37(5): p. 431-502.
10.Tanabe, T.Tohnai, N., Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat, 2002. 68-69: p. 95-114. 11.Karin, M.Ben-Neriah, Y., Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol, 2000. 18: p. 621-63.
12.Lernbecher, T.Muller, U.Wirth, T., Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature, 1993. 365(6448): p. 767-70.
13.Albert S. Baldwin., Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. Journal of Clinical Investigation 2001. 107(3): p. 241-6.
14.Sen, R.Baltimore, D., Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell, 1986. 47(6): p. 921-8.
15.Kiernan, R.Bres, V.Ng, R. W.Coudart, M. P.El Messaoudi, S.Sardet, C.Jin, D. Y.Emiliani, S.Benkirane, M., Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem, 2003. 278(4): p. 2758-66.
16.Matrisian, L.M., Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet, 1990. 6(4): p. 121-5.
17.Liotta, L. A.Stetler-Stevenson, W. G., Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 1991. 51(18 Suppl): p. 5054s-5059s.
18.Woessner, J.F., Jr., Role of matrix proteases in processing enamel proteins. Connect Tissue Res, 1998. 39(1-3): p. 69-73; discussion 141-9.
19.Kugler, A., Matrix metalloproteinases and their inhibitors. Anticancer Res, 1999. 19(2C): p. 1589-92.
20.Gomez, D. E.Alonso, D. F.Yoshiji, H.Thorgeirsson, U. P., Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol, 1997. 74(2): p. 111-22.
21.DeClerck, Y. A.Perez, N.Shimada, H.Boone, T. C.Langley, K. E.Taylor, S. M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 1992. 52(3): p. 701-8.
22.Shapiro, S. D.Kobayashi, D. K.Welgus, H. G., Identification of TIMP-2 in human alveolar macrophages. Regulation of biosynthesis is opposite to that of metalloproteinases and TIMP-1. J Biol Chem, 1992. 267(20): p. 13890-4.
23.Yang, T. T.Hawkes, S. P., Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci U S A, 1992. 89(22): p. 10676-80.
24.Greene, J.Wang, M.Liu, Y. E.Raymond, L. A.Rosen, C.Shi, Y. E., Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem, 1996. 271(48): p. 30375-80.
25.Kobori, M.Yang, Z.Gong, D.Heissmeyer, V.Zhu, H.Jung, Y. K.Gakidis, M. A.Rao, A.Sekine, T.Ikegami, F.Yuan, C.Yuan, J., Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ, 2004. 11(1): p. 123-30.
26.Lim, J. H.Ha, U. H.Woo, C. H.Xu, H.Li, J. D., CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol, 2008. 10(11): p. 2247-56.
27.Mohan, S.Konopinski, R.Yan, B.Centonze, V. E.Natarajan, M., High glucose-induced IKK-Hsp-90 interaction contributes to endothelial dysfunction. Am J Physiol Cell Physiol, 2009. 296(1): p. C182-92.
28.Vender, J. R.Laird, M. D.Dhandapani, K. M., Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery, 2008. 62(5): p. 1122-7; discussion 1027-8.
29.Tanabe, K.Nishimura, K.Dohi, S.Kozawa, O., Mechanisms of interleukin-1beta-induced GDNF release from rat glioma cells. Brain Res, 2009. 1274: p. 11-20.
30.Howe, L. R.Dannenberg, A. J., A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol, 2002. 29(3 Suppl 11): p. 111-9.
31.da Silva, A. J. M.Melo, P. A.Silva, N. M.Brito, F. V.Buarque, C. D.de Souza, D. V.Rodrigues, V. P.Pocas, E. S.Noel, F.Albuquerque, E. X.Costa, P. R., Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg Med Chem Lett, 2001. 11(3): p. 283-6.
32.Zweifel, B. S.Hardy, M. M.Anderson, G. D.Dufield, D. R.Pufahl, R. A.Masferrer, J. L., A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Eur J Pharmacol, 2008. 584(1): p. 166-74.
33.Ben-Av, P.Crofford, L. J.Wilder, R. L.Hla, T., T., Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett, 1995. 372(1): p. 83-7.
34.Kundu, N.Yang, Q.Dorsey, R.Fulton, A. M., Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer, 2001. 93(5): p. 681-6.
35.Sheng, H.Shao, J.Morrow, J. D.Beauchamp, R. D.DuBois, R. N., Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res, 1998. 58(2): p. 362-6.
36.Lee, W. J.Chen, W. K.Wang, C. J.Lin, W. L.Tseng, T. H., Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol, 2008. 226(2): p. 178-91.
37.Abdel-Ghany, M. Cheng, H. C. Elble, R. C. Pauli, B. U., The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem, 2001. 276(27): p. 25438-46.
38.Kim, D.Kim, S.Koh, H.Yoon, S. O.Chung, A. S.Cho, K. S.Chung, J., Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J, 2001. 15(11): p. 1953-62. 39.Carriero, M. V.Longanesi-Cattani, I.Bifulco, K.Maglio, O.Lista, L.Barbieri, A.Votta, G.Masucci, M. T.Arra, C.Franco, R.De Rosa, M.Stoppelli, M. P.Pavone, V., Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther, 2009. 8(9): p. 2708-17.
40. Hofmann, G. E.Glatstein, I.Schatz, F.Heller, D.Deligdisch, L. , Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol, 1994. 170(2): p. 671-6.
41.Trusolino, L.Cavassa, S.Angelini, P.Ando, M.Bertotti, A.Comoglio, P. M.Boccaccio, C., HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J, 2000. 14(11): p. 1629-40.
42.Pulukuri, S.M., Gorantla, B., and Rao, J.S., Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem, 2007. 282(49): p. 35594-603.
43.Strahl, B. D.Allis, C. D., The language of covalent histone modifications. Nature, 2000. 403(6765): p. 41-5.
44.Jeon, H. W.Lee, Y. M., Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. Mol Cancer Ther, 2010. 9(5): p. 1361-70.
45.Chang, C.F; Yang, L.Y; Chang, S.W.; Fang Y.T.; Lee, Y.J. , Total synthesis of demethylwedelolactone and wedelolactone by Cu-mediated/Pd(0)-catalysis and oxidative-cyclization. Tetrahedron, 2008. 64: p. 3661-3666.
46.Shah, M. A.Schwartz, G. K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res, 2001. 7(8): p. 2168-81.
47.Megha, T.Ferrari, F.Benvenuto, A.Bellan, C.Lalinga, A. V.Lazzi, S.Bartolommei, S.Cevenini, G.Leoncini, L.Tosi, P., p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol, 2002. 55(6): p. 461-6.
48.Sander, E. E.van Delft, S.ten Klooster, J. P.Reid, T.van der Kammen, R. A.Michiels, F.Collard, J. G., Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol, 1998. 143(5): p. 1385-98.
49.Ridley, A. J.Comoglio, P. M.Hall, A., Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol, 1995. 15(2): p. 1110-22.
50.Wang, Y.Lam, J. B.Lam, K. S.Liu, J.Lam, M. C.Hoo, R. L.Wu, D.Cooper, G. J.Xu, A., Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res, 2006. 66(23): p. 11462-70.
51.Liu, L. T.Peng, J. P.Chang, H. C.Hung, W. C., RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene, 2003. 22(51): p. 8263-70.
|